

Tomas Reinert

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9438655/tomas-reinert-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

35
papers

659
citations

12
h-index

25
g-index

40
ext. papers

854
ext. citations

4.2
avg, IF

4.52
L-index

#	Paper	IF	Citations
35	Determinants of COVID-19 Mortality in Patients With Cancer From a Community Oncology Practice in Brazil. <i>JCO Global Oncology</i> , 2021 , 7, 46-55	3.7	14
34	Real-world Data on First-line Systemic Therapy for Hormone Receptor-positive HER2-negative Metastatic Breast Cancer: A Trend Shift in the Era of CDK 4/6 Inhibitors. <i>Clinical Breast Cancer</i> , 2021 , 21, e688-e692	3	2
33	Highlights of the 17th St Gallen International Breast Cancer Conference 2021: customising local and systemic therapies. <i>Ecancermedalscience</i> , 2021 , 15, 1236	2.7	3
32	Cost-effectiveness of breast, lung, colon, prostate and cervical cancer outcomes in Brazil: a worldwide comparison. <i>Ecancermedalscience</i> , 2021 , 15, 1243	2.7	
31	Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021 , 186, 753-760	4.4	2
30	Perspectives on the Systemic Staging in Newly Diagnosed Breast Cancer. <i>Clinical Breast Cancer</i> , 2021 , 21, 309-316	3	0
29	Open questions and controversies in the systemic treatment of breast cancer. <i>Current Opinion in Oncology</i> , 2021 , 33, 591-596	4.2	0
28	Estimation of the Number of Brazilian Women Living With Metastatic Breast Cancer. <i>JCO Global Oncology</i> , 2020 , 6, 307-312	3.7	3
27	Lack of access to CDK4/6 inhibitors for premenopausal patients with metastatic breast cancer in Brazil: estimation of the number of premature deaths. <i>Ecancermedalscience</i> , 2020 , 14, 1081	2.7	0
26	Health-related quality of life before and during chemotherapy in patients with early-stage breast cancer. <i>Ecancermedalscience</i> , 2020 , 14, 1007	2.7	7
25	The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115). <i>Breast Cancer Research and Treatment</i> , 2020 , 183, 749-757	4.4	12
24	Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy. <i>Frontiers in Oncology</i> , 2020 , 10, 342	5.3	2
23	Association of Mutations and Visceral Metastasis in Patients with Estrogen Receptor-Positive Advanced Breast Cancer from Brazil. <i>Journal of Oncology</i> , 2019 , 2019, 1947215	4.5	5
22	Access to high-cost drugs for advanced breast cancer in Latin America, particularly trastuzumab. <i>Ecancermedalscience</i> , 2019 , 13, 898	2.7	19
21	Endocrine Therapy in Clinical Practice. <i>Cancer Drug Discovery and Development</i> , 2019 , 215-240	0.3	1
20	Advanced Stage at Diagnosis and Worse Clinicopathologic Features in Young Women with Breast Cancer in Brazil: A Subanalysis of the AMAZONA III Study (GBECAM 0115). <i>Journal of Global Oncology</i> , 2019 , 5, 1-10	2.6	7
19	Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2018 , 19, 23	5.4	16

18	Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2018 , 19, 24	5.4	21
17	The Challenge of Evaluating Adnexal Masses in Patients With Breast Cancer. <i>Clinical Breast Cancer</i> , 2018 , 18, e587-e594	3	0
16	Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2018 , 8, 156	5.3	20
15	Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer. <i>Chinese Clinical Oncology</i> , 2018 , 7, 25	2.3	11
14	Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018 , 168, 457-465	4.4	5
13	Emerging Innovative Therapeutic Approaches Leveraging Cyclin-Dependent Kinase Inhibitors to Treat Advanced Breast Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 1009-1019	6.1	5
12	Global Breast Cancer Research: Moving Forward. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 441-450	7.1	22
11	Avoidance of Negative Results in Adjuvant Endocrine Therapy Trials for Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2718-2719	2.2	5
10	Estimation of Premature Deaths From Lack of Access to Anti-HER2 Therapy for Advanced Breast Cancer in the Brazilian Public Health System. <i>Journal of Global Oncology</i> , 2017 , 3, 201-207	2.6	14
9	Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review. <i>Therapeutic Advances in Medical Oncology</i> , 2017 , 9, 693-709	5.4	28
8	Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer. <i>Frontiers in Oncology</i> , 2017 , 7, 26	5.3	49
7	Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2016 , 42, 694-703	2	8
6	Multidisciplinary Approach to Neoadjuvant Endocrine Therapy in Breast Cancer: A Comprehensive Review. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2016 , 38, 615-622	1.1	9
5	Definition of First-Line Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1959-60	2.2	3
4	Mechanisms of aromatase inhibitor resistance. <i>Nature Reviews Cancer</i> , 2015 , 15, 261-75	31.3	233
3	Optimal management of hormone receptor positive metastatic breast cancer in 2016. <i>Therapeutic Advances in Medical Oncology</i> , 2015 , 7, 304-20	5.4	81
2	Clinical outcomes and prognostic factors of patients with advanced non-small cell lung treated in clinical trials in Brazil: A single institution experience.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e19144-e19144	2.2	1
1	Bleomycin-Induced Lung Injury. <i>Journal of Cancer Research</i> , 2013 , 2013, 1-9		51

